Eprodisate for the treatment of renal disease in AA amyloidosis

New England Journal of Medicine

Volumn 356, Issue 23, 2007, Pages 2349-2360

  Dember, Laura M ^a   Hawkins, Philip N ^b   Hazenberg, Bouke P C ^c   Gorevic, Peter D ^d   Merlini, Giampaolo ^e   Butrimiene, Irena ^f   Livneh, Avi ^g   Lesnyak, Olga ^h   Puéchal, Xavier ⁱ   Lachmann, Helen J ^b   Obici, Laura ^e   Balshaw, Robert ^k   Garceau, Denis ^j   Hauck, Wendy ^j   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f VILNIUS UNIVERSITY   (Lithuania)

^g SHEBA MEDICAL CENTER   (Israel)

^h Regional Hospital No 1   (Russian Federation)

ⁱ CENTRE HOSPITALIER DU MANS   (France)

^j Neurochem Inc   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPRODISATE; GLYCOSAMINOGLYCAN; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AMYLOIDOSIS; ANEMIA; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTIC SYNDROME; PNEUMONIA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 34249992082     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa065644     Document Type: Article

References (21)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246-56.
3. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001;134:746-53.
4. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
5. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3.
6. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
7. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-6.
8. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
9. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
10. Snow AD, Willmer J, Kisilevsky R. Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 1987;56:120-3.
11. Lyon AW, Narindrasorasak S, Young ID, et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991;64:785-90.
12. Stenstad T, Magnus JH, Husby G. Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 1994;303:663-70.
13. Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000;7:23-5.
14. Gervais F, Morissette C, Kong X. Proteoglycans and amyloidogenic proteins in peripheral amyloidosis. Curr Med Chem Immun Endocr Metab Agents 2003;3:361-70.
15. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143-8.
16. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001;8:Suppl 1:28-35.
17. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102.
18. Wilkins J, Gallimore JR, Tennent GA, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994;40:1284-90.
19. Crowley S, Feinfeld DA, Janis R. Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis. Am J Kidney Dis 1989;13:333-5.
20. Verschueren P, Lensen F, Lerut E, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003;62:368-9.
21. Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28:537-47.